交易 Bristol Myers 差价合约 — 实时图表

您好, user_no_name

立即交易

存入

退出
登录注册
ZH

语言

English English (Global)

English English (EU)

English English (UK)

English English (AU)

English English (ZA)

English English (St. Vincent)

Deutsch German

Español Spanish (Latam)

Español Spanish (Spain)

Français French

Dansk Danish

Italiano Italian

Nederlands Dutch

العربية Arabic

Svenka Swedish

Tiếng việt Vietnamese

Bahasa Melayu Malay

ภาษาไทย Thai

繁體中文 Traditional Chinese

简体中文 Simplified Chinese

Tagalog Tagalog

தமிழ் Tamil

हिन्दी Hindi

Português Portuguese

Bahasa Indonesia Indonesian

한국어 Korean

English English (BVI)
市场

产品

外汇

股票

商品

指数

加密貨幣CFD

ETFs

债券
交易

交易平台

Web 平台

应用

TradingView

MT4

MT5

Trading Central

交易工具

差价合约交易计算器

外汇交易保证金计算器

商品利润计算器

外汇交易利润计算器

经济事件日历

交易信息

差价合约交易

差价合约资产列表

交易条件

交易时段

到期日

近期交易休市日

每周到期展期

交易功能

市场深度
学习

学习交易

术语表

教育中心

交易基础知识

视频库

新闻与分析

新闻

社区
推广

marketsClub

欢迎奖金

积分奖

推荐促销
加盟

加盟

IB
关于

Markets.com 简介

为何选择 markets.com

全球服务

集团简介

奖项和媒体

帮助与支持

常见问题解答

帮助中心

联系客服

投诉

数据与安全

安全上网

Cookie 披露声明

法律资源包

合法交易条例

法规

搜索

语言

登录注册

BristolMyers 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

历史数据

日期	关闭	更改	更改(%)：	开盘价	高	低

BristolMyers news

Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices

Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices

Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

信息

点差

0.29

点差(%)

0.6258 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期三

13:31 - 19:59

星期一

13:31-19:59

星期二

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

96340680704

在外流通股份

2035079936

财报日（下一）

2001-08-07

股息收益率

2025-08-01

除息日

2025-07-03

远期年度股息率

2.48

远期年股息率

0.0536

每股收益

2.68

详细了解此金融票据

Bristol Myers Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.